Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Net Cash Flow: 2009-2024

Historic Net Cash Flow for Catalyst Pharmaceuticals (CPRX) over the last 16 years, with Dec 2024 value amounting to $379.9 million.

  • Catalyst Pharmaceuticals' Net Cash Flow fell 44.34% to $37.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $247.6 million, marking a year-over-year decrease of 22.96%. This contributed to the annual value of $379.9 million for FY2024, which is 336.33% up from last year.
  • As of FY2024, Catalyst Pharmaceuticals' Net Cash Flow stood at $379.9 million, which was up 336.33% from -$160.8 million recorded in FY2023.
  • Over the past 5 years, Catalyst Pharmaceuticals' Net Cash Flow peaked at $379.9 million during FY2024, and registered a low of -$160.8 million during FY2023.
  • For the 3-year period, Catalyst Pharmaceuticals' Net Cash Flow averaged around $115.4 million, with its median value being $127.0 million (2022).
  • As far as peak fluctuations go, Catalyst Pharmaceuticals' Net Cash Flow tumbled by 226.63% in 2023, and later soared by 336.33% in 2024.
  • Catalyst Pharmaceuticals' Net Cash Flow (Yearly) stood at $40.7 million in 2020, then rose by 1.19% to $41.2 million in 2021, then spiked by 208.07% to $127.0 million in 2022, then plummeted by 226.63% to -$160.8 million in 2023, then spiked by 336.33% to $379.9 million in 2024.